Onkologie. 2018:12(4):198-202 | DOI: 10.36290/xon.2018.036

Bevacizumab in epithelial ovarian cancer treatment, efficiency and risks

Jana Ďurková
Oddelenie rádioterapie a klinickej onkológie, FN Nitra, Slovenská republika

Ovarian cancer represents serious medical and social problem worldwide. Ovarian cancer is the leading cause of death from gynaecologicalcancer in developed countries, causes more than 50 % deaths in this tumor group. More than 75 % of women haveadvanced disease (International Federation of Gynecology and Obstetrics [FIGO] stage IIIC or IV) at diagnosis, and have a 5-yearsurvival rate of less than 25 %. Diagnostic tools for screening have not been found yet. Treatment possibilities (surgery, chemotherapy)are insufficient while high tendency to recurrence and chemoresistance occurs. Bevacizumab represents progress inthe treatment of this disease and is one of the key improvements for the last 15 years. There is no doubt about its effects on thetreatment of ovarian cancer, but still many questions for example about the optimal timing of treatment are unresponsive. Thebenefit of maintenance treatment and the optimal duration of administration is unclear too.

Keywords: ovarian cancer, bevacizumab, chemotherapy, efficiency, progression free survival

Published: September 1, 2018  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Ďurková J. Bevacizumab in epithelial ovarian cancer treatment, efficiency and risks. Onkologie. 2018;12(4):198-202. doi: 10.36290/xon.2018.036.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Katsumata N, Yasuda M, Isonishi S, et al. Long-term results of dose-dense paclitaxel and carboplatin versus conventional paclitaxel and carboplatin for treatment of advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer (JGOG 3016): a randomised, controlled, open-label trial. Lancet Oncol. 2013; 14: 1020-1026. Go to original source... Go to PubMed...
    2. Armstrong DK, Bundy B, Wenzel L, et al. Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N Engl J Med. 2006; 354: 34-43. Go to original source... Go to PubMed...
    3. Vergote I, Tropé CG, Amant F, et al. Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer. N Engl J Med. 2010; 363: 943-945. Go to original source... Go to PubMed...
    4. Kehoe S, Hook J, Nankivell M, et al. Primary chemotherapy versus primary surgery for newly diagnosed advanced ovarian cancer (CHORUS): an open-label, randomised, controlled, non-inferiority trial. Lancet. 2015; 386: 249-257. Go to original source... Go to PubMed...
    5. van Meurs HS,Tajik P, Hof MH, et al. Which patients benefit most from primary surgery or neoadjuvant chemotherapy in stage IIIC or IV ovarian cancer? An exploratory analysis of the European Organisation for Research and Treatment of Cancer 55971 randomised trial. Eur J Cancer. 2013; 49(15): 3191-3201. Go to original source... Go to PubMed...
    6. Burger RA, Brady MF, Bookman MA, et al. Incorporation of bevacizumab in the primary treatment of ovarian cancer. N Engl J Med.2011; 365: 2473-2483. Go to original source... Go to PubMed...
    7. Perren TJ, Swart AM, Ledermann JA, et al. A phase 3 trial of bevacizumab in ovarian cancer. N Engl J Med.2011; 365: 2484-2496. Go to original source... Go to PubMed...
    8. Aghajanian C, Blank SV, Judson PL, et al.OCEANS: a randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinumsensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer. J Clin Oncol.2012; 30: 2039-2045. Go to original source... Go to PubMed...
    9. Pujade-Lauraine E, Hilpert F, Weber B, et al. Bevacizumab combined with chemotherapy for platinumresistant recurrent ovarian cancer: the AURELIA open label randomized phase III trial. J Clin Oncol 2014; 32: 1302-1308. Go to original source... Go to PubMed...
    10. Chi DS, Musa F, Dao F, et al. An analysis of patients with bulky advanced stage ovarian, tubal, and peritoneal carcinoma treated with primary debulking surgery (PDS) during an identical time period as the randomized EORTC-NCIC trial of PDS vs neoadjuvant chemotherapy (NACT). Gynecol Oncol. 2012;124: 10-14. Go to original source... Go to PubMed...
    11. Mueller JJ, Zhou QC, Iasonos A, et al. Neoadjuvant chemotherapy and primary debulking surgery utilization for advanced-stage ovarian cancer at a comprehensive cancer center. Gynecol Oncol. 2016; 140: 436-442. Go to original source... Go to PubMed...
    12. Petrillo M, Paris I, Vizzielli G, et al. Neoadjuvant Chemotherapy Followed by Maintenance therapyWith or Without Bevacizumab in Unresectable High-Grade Serous Ovarian Cancer: A Case-Control Study. Ann Surg Oncol. 2015; 3: 952-958. Go to original source... Go to PubMed...
    13. Mendiola C, Davidenko I, Colombo N, et al. ROSiA: a single-arm study in more than 1000 patients (pts) receiving front-line bevacizumab (BEV) + chemotherapy (CT) for ovarian cancer (OC). Presented at: the ESMO Congress 2012, poster č.978P. Go to original source...
    14. Aghajanian C, Nycum LR, Goff B, et al. Updated overall survival analysis in OCEANS, a randomized phase 3 trial of gemcitabine (G) + carboplatin (C) and bevacizumab (BV) or placebo (PL) followed by BV or PL in platinum-sensitive recurrent epithelial ovarian (ROC), primary peritoneal (PPC), or fallopian tube cancer (FTC), [abstract]. Presented at: the ESMO Congress; 2012. Abstract 9670. Go to original source...
    15. Hiroyuki Y, Akira Y, Keiichi F. Drug Design, Development and Therapy 2015; 9: 2351-235Critical appraisal of bevacizumab in the treatment of ovarian cancer (PDF Download Available). Available from: https://www.researchgate.net/publication/277897866_Critical_appraisal_of_bevacizumab_in_the_treatment_of_ovarian_cancer [accessed Jan 10 2018]. Go to original source... Go to PubMed...
    16. Rossi L, Verrico M, Zaccarelli E, et al. Bevacizumab in ovarian cancer:A critical rewiev of phase III studies, Oncotarget, 2017; 8(7): 12389-12405 avaible from: https://www.researchgate.net/publication/309959711_Bevacizumab_in_ovarian_cancer_A_critical_review_of_phase_III_studies [accessed Jan 10 2018]. Go to original source... Go to PubMed...
    17. Roncolato FT, Gibbs E, Lee CK, et al. Quality of life predicts overall survival in women with platinum-resistant ovarian cancer: an AURELIA substudy., Ann Oncol 2017; 28(8): 1849-1855. Go to original source... Go to PubMed...
    18. Garanová H. Začlenenie bevacizumabu do prvej línie liečby karcinómu vaječníka - retrospektívna analýza, Onkológia, 2015; 10(5): 325-328.

    Return to the content


    Oncology

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.